Entera Bio (NASDAQ:ENTX) is scheduled to be announcing its earnings results before the market opens on Tuesday, August 20th.
Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings data on Thursday, June 27th. The company reported ($0.26) earnings per share (EPS) for the quarter.
ENTX opened at $2.84 on Friday. The firm has a market capitalization of $27.66 million, a P/E ratio of 0.18 and a beta of 2.38. The firm’s 50 day moving average is $3.19 and its 200-day moving average is $3.86. Entera Bio has a 52-week low of $1.35 and a 52-week high of $6.40. The company has a quick ratio of 4.62, a current ratio of 4.62 and a debt-to-equity ratio of 0.03.
ENTX has been the topic of a number of analyst reports. Maxim Group set a $8.00 price objective on shares of Entera Bio and gave the company a “buy” rating in a research note on Wednesday, July 31st. ValuEngine upgraded shares of Entera Bio from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
About Entera Bio
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism.
Further Reading: Trading Strategy Methods and Types
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.